{"disease":{"id":"advanced-malignant-mesothelioma","name":"advanced malignant mesothelioma"},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"ipilimumab","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"yervoy","indication_name":"Unresectable advanced or recurrent malignant pleural mesothelioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01655225","title":"A Study of LY3023414 in Participants With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT04491942","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02141347","title":"Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT04462809","title":"Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03507452","title":"First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05498597","title":"AMT-151 in Patients With Selected Advanced Solid Tumours","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Multitude Therapeutics Inc.","has_results":false},{"nct_id":"NCT02535312","title":"Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04290325","title":"HMPL-453 in Advanced Malignant Mesothelioma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":27,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT05714553","title":"NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"NuCana plc","has_results":false},{"nct_id":"NCT02408016","title":"Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT04166734","title":"Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":true},{"nct_id":"NCT03920839","title":"INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Incyte Corporation","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}